Get the Stockscreener App
3.64
1.36%
-0.05
After Hours:
3.65
0.010
+0.27%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.64, with a volume of 1.76M.
It is down -1.36% in the last 24 hours and up +0.55% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$3.69
Open:
$3.69
24h Volume:
1.76M
Relative Volume:
0.32
Market Cap:
$321.26M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-2.2195
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-3.70%
1M Performance:
+0.55%
6M Performance:
-34.41%
1Y Performance:
-48.73%
1-Day Range:
$3.63
$3.725
1-Week Range:
$3.60
$3.82
52-Week Range:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.64 | 323.90M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel - GlobeNewswire
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025ALT - PR Newswire
Invesco Ltd. Sells 165,958 Shares of Altimmune, Inc. $ALT - MarketBeat
Faruqi & Faruqi Reminds Altimmune Investors of the Pending - GlobeNewswire
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - GlobeNewswire Inc.
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights – ALT - GlobeNewswire
Altimmune, Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your RightsALT - Barchart.com
Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune, - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming DeadlinesALT | FinancialContent - FinancialContent
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Altimmune at Morgan Stanley Conference: Strategic Focus on Liver Health - Investing.com
Hsbc Holdings PLC Acquires Shares of 72,258 Altimmune, Inc. $ALT - MarketBeat
Altimmune: Pemvidutide Shows Promise In MASH, But Lacks Competitive Edge - Seeking Alpha
ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. - GlobeNewswire
Levi & Korsinsky Helps Retail Investors SueWallSt Over Alleged Fraud by Altimmune, Inc - ACCESS Newswire
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Louisiana First News
Analyzing Chugai Pharmaceutical (OTCMKTS:CHGCY) & Altimmune (NASDAQ:ALT) - Defense World
Burned by Altimmune, Inc.? Contact Levi & Korsinsky to SueWallSt and Fight Back - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Altimmune, Inc. (ALT) of a Class Action Lawsuit and an Upcoming Deadline - NewMediaWire
Important Notice to Long-Term Shareholders of Altimmune, - GlobeNewswire
The Gross Law Firm Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025ALT - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
How high can Altimmune Inc. stock goPortfolio Value Summary & Intraday High Probability Setup Alerts - Newser
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - MarketScreener
What is Altimmune Inc.’s valuation compared to sectorProfit Target & Weekly Return Optimization Alerts - خودرو بانک
The Risks of Over-Optimism in Telecommunications: A Case Study of Unicycive Therapeutics and Charter Communications Class-Action Allegations - AInvest
Securities Fraud Class Action Filed Against Altimmune, Inc. (ALT)Levi & Korsinsky Reminds Investors of October 6, 2025 - ACCESS Newswire
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. - GlobeNewswire
Will Altimmune Inc. outperform the market2025 Technical Overview & Safe Swing Trade Setups - Newser
Altimmune, Inc. shares rise 4.64% intraday after completing enrollment in HepTcell Phase II clinical trial. - AInvest
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. InvestorsLead Plaintiff Deadline October 6, 2025 - ACCESS Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Securities Class Action Lawsuit Filed Against Altimmune, Inc. (ALT)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
Class Action Filed Against Altimmune, Inc. (ALT)October 6, 2025 Deadline to JoinContact Levi & Korsinsky - FinancialContent
Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025ALT - PR Newswire
What recovery options are there for Altimmune Inc.July 2025 Trends & Free Low Drawdown Momentum Trade Ideas - Newser
Using data models to predict Altimmune Inc. stock movementJuly 2025 Trends & Consistent Profit Trade Alerts - Newser
Will Altimmune Inc. see short term momentumJuly 2025 PostEarnings & Weekly Watchlist for Hot Stocks - Newser
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewswire
Investors in Altimmune, Inc. (ALT): Protect Your RightsContact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Securities Lawsuit Alert: Altimmune, Inc. (ALT)Contact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Will breakout in Altimmune Inc. lead to full recoveryJuly 2025 Trends & Safe Investment Capital Preservation Plans - Newser
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
What MACD signals say about Altimmune Inc.Quarterly Portfolio Review & Risk Managed Investment Strategies - Newser
Identifying reversal signals in Altimmune Inc.July 2025 Setups & Fast Entry Momentum Trade Alerts - Newser
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):